H. Lundbeck A/S
Feb 6, 2013

Full year report 2012 - Lundbeck delivers on guidance and sales of New Products increase more than 70%

Attachment

H. Lundbeck A/S (Lundbeck) announces its financial results for 2012, which are in line with expectations for the year, excluding restructuring charges. Revenue for 2012 was DKK 14,227 million, excluding Lexapro in the US, which is an increase of 6% compared with 2011. Growth was driven primarily by Lundbeck's New Products*, which generated revenue of DKK 2,141 million, an increase of 71% compared with 2011. Profits were impacted by the loss of Lexapro® revenue in the US, due to patent expiration, and EBIT for 2012 was DKK 2,177 million, excluding restructuring costs. This corresponds to an EBIT margin of 14.7% for the year.


Distribution of revenue

DKK million Q4 2012 Q4 2011 Growth Growth
 in local
 currency
FY 2012 FY 2011  Growth Growth
 in local
 currency
New Products* 582 374 55% 49% 2,141 1,253 71% 59%
                 
Cipralex 1,501 1,433 5% 3% 5,827 5,957 (2%) (3%)
Ebixa 677 650 4% 4% 2,803 2,751 2% 2%
Azilect 326 309 6% 6% 1,224 1,187 3% 4%
Xenazine 322 242 33% 27% 1,197 852 40% 30%
                 
Europe 1,960 1,907 3% 2% 7,734 7,988 (3%) (3%)
USA (excl. Lexapro) 556 418 33% 27% 2,099 1,627 29% 20%
International Markets 966 866 11% 10% 3,768 3,468 9% 7%
                 
Total revenue 3,845 3,829 0% (1%) 14,802 16,007 (8%) (8%)

*New Products include Xenazine, Sabril, Sycrest, Lexapro (Japan), Onfi and Treanda

In connection with the full year report, Lundbeck's President and CEO Ulf Wiinberg said:
"2012 was an exciting year for Lundbeck. We have launched two new products, and our pipeline has shown a significant development. Going into 2013 we are planning to launch three additional new products — BrintellixTM, Abilify® once-monthly and SelincroTM."